
HTGF et al. inject €4.3m into Algiax Pharmaceuticals
High-Tech Gründerfonds (HTGF), private investors and promotional bank KfW have provided German biotech company Algiax Pharmaceuticals with a €4.3m seed funding round.
Algiax will use the capital to further develop its products and gain approval for the clinical testing stage of its solutions.
Company
Founded in 2011, Algiax develops drugs addressing central nervous system (CNS) illnesses and dysfunctions, with a focus on neuropathic pain. The company is headquartered in Erkrath.
People
Dr Martin Pfister led the deal for HTGF. KfW was represented by Dr Detlev Riesner. Dr Jürgen Schumacher is co-founder and managing director of Algiax.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater